Health Canada Approves Pembrolizumab/Surgery in Locally Advanced HNSCC
Written by
Cancer Network
Published
0
comments
0
min
Results from the phase 3 KEYNOTE-689 trial supported the agency’s approval of the pembrolizumab/surgery regimen in PD-L1–positive head and neck cancer.